factor-B (NF-B) ligand (RANKL), are essential and sufficient (3) (4) (5) . M-CSF, which is imperative for macrophage maturation, binds to its receptor in early osteoclast precursors, thereby providing signals required for their survival, proliferation, and osteoclast development (6, 7) . On the other hand, RANKL, a member of the tumor necrosis factor (TNF) family, binds to its receptor RANK and activates NF-B, which is associated with osteoclastic differentiation and activation. These, in turn, prompt activation primarily via phosphorylation events such as activation of the cytoplasmic inhibitor of NF-B (IB) kinase, the IB and NF-B pathway, and the mitogen-activated protein (MAP) kinase pathway (3). TNF-␣, which is produced by many types of cells including monocytes and macrophages, has been proposed to be involved in bone resorption, particularly in inflammatory bone diseases. It was also reported that TNF-␣ and interleukin-1␣ play important roles in bone loss associated with osteoporosis (8) . TNF-␣ also stimulates formation of multinucleated cells with the characteristics of osteoclasts in human bone marrow cultures (9) . TNF-␣ induces a number of biological responses via two cell surface receptors termed TNF receptor-1 (TNFR1) and TNFR2 (10 -12) . Both TNFR1 and TNFR2 can transduce intracellular signals that stimulate the proteolytic breakdown of IB (13) (14) (15) (16) . The activated NF-B is then translocated into the nucleus where it induces the transcription of several genes. In the fibrosarcoma cell line L929, exogenous generated bovine brain gangliosides prevent TNF-␣-induced apoptosis (17) . This inhibitory effect may be caused by an interference of gangliosides with intracellular signal transduction pathways, resulting in an inhibition of the activation of DNA-cleaving endonucleases. Moreover, treatment of cultured melanocytes with TNF-␣ results in a change in morphology and greatly enhanced expression of disialoganglioside 3 (GD3) (18) . This effect is specific; no other ganglioside is affected with the exception of an increase in monosialoganglioside 3 (GM3). These results suggest that glycosphingolipids (GSLs), especially gangliosides, are important to TNF-␣ signaling and TNF-␣-induced cell fates. Although RANKL activates almost the same signal transduction path-way as TNF-␣, the effects of GSLs on osteoclastogenesis by RANKL have never been reported.
GSLs have been implicated as mediators of cell adhesion and modulators of signal transduction. These glycolipids compose lipid rafts, glycolipid-enriched microdomains, on the cell surface (19) . The majority are clustered and associated closely with single or multiple signal transducer molecules; for example, GM3 ganglioside organized with c-Src, Rho, focal adhesion kinase, and Ras in B16 melanoma cells, and GD3 associated with Src family tyrosine kinase Lyn in the rat brain (20 -22) .
D-Threo-1-phenyl-2-decanoylamin-3-morpholino-1-propanol (D-PDMP) inhibits glucosylceramide (GlcCer) synthase and thus leads to extensive depletion of the glycosphingolipids derived from GlcCer (23) . It has proven to be a useful tool for studying various functional roles of endogenous GSLs and their rafts in the living cell. For example, in NIH3T3 fibroblasts, which have overexpressing receptors for insulin-like growth factor I, D-PDMP has been reported to prevent the proliferative response to either insulin-like growth factor I or serum by blocking cell cycle-dependent kinases (24, 25) , although it did not affect early signal transduction events in response to these stimuli. In a neuronal culture system, D-PDMP has been reported to affect growth of murine neuroblastoma (26) . D-PDMP also inhibits the axonal growth of hippocampal neurons (27) and neurite outgrowth of a rat pheochromocytoma cell line PC12 (28) .
In this study, we investigated the effect of GSLs on osteoclastogenesis induced by M-CSF and RANKL. We show here that D-PDMP completely inhibits osteoclast formation. Furthermore, D-PDMP inhibits the responses in both phosphorylation of IB and extracellular signal-regulated kinase 1/2 (ERK1/2) induced by RANKL, and LacCer rescued the reduction of phosphorylation and RANKL-induced osteoclastogenesis.
EXPERIMENTAL PROCEDURES
Reagents-Soluble murine RANKL was expressed in Sf9 cells and purified from culture medium with nickel-nitrilotriacetic acid chromatography as described previously (29, 30) . Recombinant murine M-CSF was purchased from R&D Systems (Minneapolis). All glycosphingolipids and sphingolipids used in this study were purchased from Sigma.
Cell Culture-Bone marrow cells obtained from tibias and femurs of 4 -6-week-old male ddY mice were passed through a Sephadex G-10 (Amersham Pharmacia Biotech) column as described previously (31, 32) . Purified bone marrow cells were then cultured at 1.5 ϫ 10 6 cells/ml in 48-well plates for 3 or 5 days, under osteoclastogenic conditions, consisting of ␣-minimal essential medium supplemented with 10% heat-inactivated fetal bovine serum at 37°C in 5% CO 2 in the presence of 10 ng/ml M-CSF and 50 ng/ml RANKL. The medium was changed on day 2 of culture and supplemented with M-CSF and RANKL. D-PDMP treatment forced the addition of D-PDMP at 2.5-30 M with M-CSF and RANKL in growth medium.
TRAP Staining-Osteoclasts were identified as those cells staining positively for tartrate-resistant acid phosphatase (TRAP). On the 3rd or 5th day of culture, cells were fixed in 4% paraformaldehyde in phosphate-buffered saline solution for 30 min at room temperature. After treatment with 0.2% Triton X-100 in phosphate-buffered saline for 5 min, the cells were stained for TRAP as described previously (29) . TRAP-positive mono-or multinuclear cells were counted. Cells containing four or more nuclei were counted as multinuclear cells.
Extraction of Sphingolipids and Glycosphingolipids-Sphingolipids and glycosphingolipids were extracted as described previously (33, 34) . Briefly, sphingolipids and glycosphingolipids were extracted from about 400 l of packed bone marrow cells treated with 10 ng/ml M-CSF and 50 ng/ml RANKL and treated with 10 ng/ml M-CSF, 50 for neutral glycolipids, and chloroform:methanol (9:1) for the separation of ceramides and then sprayed with resorcinol for detection of bands for gangliosides. The expression levels of neutral glycolipids and sphingolipids were estimated using a Bio-Image analyzer BAS2000 (Fuji Film, Tokyo). For standard gangliosides, bovine brain ganglioside mixture (Wako Chemical Inc., Tokyo) and GM3 (Snow-brand, Tokyo) were used. Each band intensity was measured by NIH Image 1.61.
Western Immunoblotting-Purified bone marrow cells were then cultured in the presence of 10 ng/ml M-CSF and 50 ng/ml RANKL with or without 30 M D-PDMP or 30 M D-PDMP and 0.5 M LacCer in 100-mm tissue culture plates in serum-containing medium for 3 days. Before RANKL or M-CSF treatment, the medium was washed and replaced with serum-free medium, and the cells were incubated for 2 h. The cells were then incubated with 50 ng/ml RANKL or 10 ng/ml M-CSF for the appropriate times in the individual experiments at 37°C. After these treatments, the medium was removed, and the cells were washed three times with phosphate-buffered saline containing 1 mM sodium vanadate (Na 3 VO 4 ), then solubilized in 200 l of lysis buffer (10 mM Tris-HCl, pH 7.4, 150 mM NaCl, 10 mM MgCl 2 , 0.5% Nonidet P-40, 1 mM phenylmethylsulfonyl fluoride, 20 units/ml aprotinin). Lysed cells were centrifuged at 14,000 rpm for 30 min, and the protein concentration of each sample was measured with micro-BCA protein assay reagent (Pierce Chemical Co.). The samples were denatured in SDS sample buffer and loaded onto a 12% SDS-polyacrylamide gel. 20 g of lysate protein was applied to each lane. After SDS-polyacrylamide gel electrophoresis, the proteins were transferred onto a polyvinylidine difluoride membrane and immunoblotted with anti-IB, anti-phospho-IB (Cell Signaling Technology, Inc.), anti-MAP kinase, and anti-phospho-MAP kinase (New England Biolabs) and then visualized using an ECL kit (Amersham Pharmacia Biotech).
RT-PCR-Total RNA was extracted using Trizol reagent (Life Technologies, Inc.), and first strand cDNA was synthesized using ReveTra Ace (TOYOBO, Osaka, Japan). For PCR analysis, cDNA was amplified by Taq DNA polymerase (Takara Biomedicals, Tokyo). A thermal cycle of 94°C for 30 s, 60°C for 30 s, and 72°C for 1 min was performed using a program of 29 cycles for RANK. Glyceraldehyde-3-phosphate dehydrogenase, an internal control for PCR, was repeated for 23 cycles at 55°C for 1 min of annealing. The amplified products were separated by electrophoresis on a 1.5% agarose gel. Primer sequences used for mouse RANK were 5Ј-CGCCATGGCCCCGCGCGCCCGG-3Ј (21-42) and 5Ј-GGCAGGTAAGCCTGGGCCTCC-3Ј (662-642), and for glyceraldehyde-3-phosphate dehydrogenase were 5Ј-ATGTCGTGGAGTCTACTGGC-3Ј (321-340) and 5Ј-TGACCTTGCCCACAGCCTTG-3Ј (682-701). The predicted size of the each fragment are 642 and 381 base pairs, respectively.
RESULTS

Expression of Sphingolipids and Glycosphingolipids Changed after Stimulation of RANKL and D-PDMP-Isolated
bone marrow cells from ddY mice, a precursor of osteoclasts, were cultured with 10 ng/ml M-CSF and 50 ng/ml RANKL. To analyze the change in sphingolipids and sphingoglycolipids during the osteoclast differentiation, we isolated and performed thin layer chromatography analysis as described under "Experimental Procedures." GM3 and GM1 ganglioside expression was increased at 3 days after adding M-CSF and RANKL (Fig. 1B) . The ganglioside including GM3 and GM1 expression was not observed under the stimulation of M-CSF without RANKL (data not shown). Ceramide, sphingosine, and sphinganine expression was not changed by M-CSF and RANKL (Fig. 1C) . GM3 and GM1 expression induced by M-CSF and RANKL was completely inhibited by a 30 M D-PDMP treatment (Fig. 1B) . GlcCer and LacCer expression was also reduced by D-PDMP. On the other hand, ceramide was increased 2.3 times after a D-PDMP treatment (Fig. 1C) . Sphingosine and sphinganine synthesis was not changed by D-PDMP. The other complex gangliosides, except GM3 and GM1, were not expressed under any condition. Osteoclastogenesis in GM2/GD2-TϪ/Ϫ Mice-We used GM2/GD2 synthase (GM2/GD2-T)Ϫ/Ϫ mice, disrupting complex gangliosides (35, 36) to determine which glycolipids are important to M-CSF-and RANKL-induced osteoclastogenesis. We found a small decrease in the number of osteoclasts from GM2/GD2-TϪ/Ϫ mice compared with wild type and heterozygous mice (Fig. 3) . TRAP-positive mononuclear cell formation in GM2/GD2-TϪ/Ϫ mice was reduced ϳ18% on the 3rd day poststimulation with M-CSF and RANKL. In addition, TRAPpositive multinuclear cell formation in GM2/GD2-TϪ/Ϫ mice was reduced ϳ16% on day 5. As a result of mononuclear to multinuclear cell formation in osteoclast differentiation, mononuclear cell numbers were gradually reduced in 5 days, but the mononuclear cell number in GM2/GD2-TϪ/Ϫ mice was still high compared with the wild type mice. However, it was much less significant than the effect of D-PDMP. In the bone marrow cells of GM2/GD2-TϪ/Ϫ mice, D-PDMP treatment dramatically reduced TRAP-positive mononuclear and multinuclear cell formation. These findings support the possibility that the other glycolipids remained in GM2/GD2-TϪ/Ϫ mice. For example, GM3, LacCer, and GlcCer may be important to induce osteoclastogenesis, especially in TRAP-positive mononuclear cell formation.
Restoration by Exogenous LacCer of PDMP-blocked Osteoclast Differentiation-We thought that the glycolipids that remained in GM2/GD2-TϪ/Ϫ mice were important to osteoclast formation. To determine which glycolipids were important in osteoclastogenesis, GM3, GD3, LacCer, GlcCer, and C2-ceramide were added to cultured bone marrow cells treated with 10 ng/ml M-CSF, 50 ng/ml RANKL, and 30 M D-PDMP (Fig. 4) . TRAP-positive mononuclear and multinuclear cells were counted at 3 and 5 days after stimulation with these factors. The addition of 0.5 M LacCer yielded a 65% recovery of TRAPpositive mononuclear cell formation 3 days after stimulation (Fig. 4B) . 5 M GM3 and GM1 were also recovered, but less effectively compared with the LacCer treatment (Fig. 4B) . The other glycolipids, GD3 and GlcCer, and C2-ceramide, were not effective in the induction of TRAP-positive mononuclear cell. It was observed in this study that no glycolipid or ceramides used produced TRAP-positive multinuclear cells containing four or more nuclei (data not shown).
Glycosphingolipids were decreased in presence of D-PDMP. However, ceramide and its other derivatives were increased by D-PDMP treatment. In fact, ceramide was increased after treatment with D-PDMP (Fig. 1C) . To determine the effect of increased ceramide on osteoclastogenesis induced by M-CSF and RANKL, C2-ceramide and sphingosine were added to our culture system without D-PDMP. C2-ceramide and sphingosine did not affect TRAP-positive mononuclear cell formation (Fig.  4C) . Moreover, TRAP-positive multinuclear cell formation was observed in the presence of C2-ceramide at the same level as the control (date not shown).
Phosphorylation of ERK1/2 and IB by RANKL Is Diminished by D-PDMP and Recovered by LacCer-RANKL induced recruitment of TNF-associated factors 2 and 6 to the cytoplasmic tail of RANK with activated IB kinase and IB phosphorylation. RANKL also activated the MAP kinase cascade (37, 38) . These signals are essential for osteoclast differentiation and survival. To determine the effect of glycolipids on RANKLinduced signal transduction, we examined the expression and phosphorylation of IB and ERK1/2 in RANKL-treated purified bone marrow cells with and without D-PDMP. IB phosphorylation was observed at 5 min after stimulation of RANKL in control bone marrow cells, and the phosphorylation was sustained for 60 min (Fig. 5A) . Alternatively, RANKL-induced phosphorylation of IB was reduced significantly in D-PDMPtreated cells. Similar results were observed in the phosphorylation of ERK1/2 after treatment with D-PDMP (Fig. 5B) . With the addition of LacCer in culture medium 3 days prior to RANKL stimulation, D-PDMP-treated IB and ERK1/2 phosphorylation were recovered by control cell levels (Fig. 5, A and   B) . After the addition of M-CSF, ERK1/2 was transiently activated, and the phosphorylation was reduced markedly (Fig.  5C) . The activation pattern of ERK1/2 was different from RANKL-induced ERK1/2 phosphorylation. In cells treated with D-PDMP, ERK1/2 phosphorylation-induced M-CSF was about 50% reduced compared with cells that were not treated with D-PDMP. Reduced phosphorylation by D-PDMP was also recovered with exogenously generated LacCer (Fig. 5C) .
Expression of RANK after Adding M-CSF Is Inhibited by D-PDMP and Recovered by LacCer-RANKL binds to its recep-
tor RANK and then activates the downstream molecules, including NF-B and ERK1/2. The RANK expression level is important to the signal transduction of RANKL. We determined the expression level of RANK after treatment with D-PDMP by semiquantitative reverse transcription-PCR (Fig. 6) . In purified bone marrow cells, RANK was not expressed without M-CSF and RANKL. RANK expression was induced after 
DISCUSSION
Changing of glycolipid synthesis and their expression patterns have been observed during cellular differentiation and development as well as with exposure to several cytokines and growth factors. Many of these studies were performed by adding exogenous glycolipids into the culture medium of the cell lines under investigation. There was modulation of functions of platelet-derived growth factor receptor (39), epidermal growth factor receptor (40, 41) , insulin receptor (42), insulin-like receptor (43) and nerve growth factor (44) . In the present study, we observed the change of glycolipid expression during osteoclastogenesis. Among the gangliosides, only GM3 and GM1 were observed in bone marrow cells after adding M-CSF and RANKL; no other ganglioside expression was observed before stimulation of these factors (Fig. 1B) . Therefore, we thought that GM3, GM1 and the precursors of these gangliosides, LacCer and GlcCer, were important for M-CSF-and RANKLinduced osteoclastogenesis.
D-PDMP inhibits glucosylceramide synthase and deprives the cell surface sugar chain for glycolipids; therefore, it is useful for analysis of glycolipid function (23) . We employed D-PDMP to assess whether the inhibition of glycolipids including gangliosides would affect osteoclast formation induced by M-CSF and RANKL. In our in vitro culture system for osteoclasts, D-PDMP completely inhibited the osteoclastogenesis induced by M-CSF and RANKL. These results suggest that GSLs are necessary for M-CSF or RANKL signaling. We also used bone marrow cells of GM2/GD2-TϪ/Ϫ mice to determine which glycolipids are important for M-CSF-and RANKL-induced osteoclastogenesis as a preliminary experiment. These mice had disrupted complex gangliosides and showed aspermatogenesis and the attenuation of interleukin-2-induced Tcell activation (35, 36, 45) . In GM2/GD2-TϪ/Ϫ mice-derived cells, osteoclast formation was nearly the same level compared with wild type mice, but there was a little inhibition in the number of TRAP-positive mononuclear cells after 3 days of stimulation with M-CSF and RANKL. After 5 days of M-CSF and RANKL supplementation, the number of TRAP-positive multinuclear cells in GM2/GD2-TϪ/Ϫ mice was a little smaller than GM2/GD2-Tϩ/Ϫ mice. The number of TRAP-positive mononuclear cells in GM2/GD2-TϪ/Ϫ mice was a little larger than in GM2/GD2-Tϩ/Ϫ mice. In cells derived from GM2/GD2-Tϩ/Ϫ mice, cell fusion of TRAP-positive mononuclear cells may be inhibited. Several adhesion molecules, for example integrins and intercellular adhesion molecule-1 (ICAM-1), are important for cell-to-cell adhesion and fusion in osteoclasts. ICAM-1 was also highly expressed in mononuclear cell cultures in forming preosteoclast-like mononuclear cells (46) . In the bone marrow culture system for multinuclear cell formation, significant inhibition was observed with the addition of ICAM-1-binding peptide (46) . These results strongly suggest the involvement of integrins and ICAM-1 in osteoclastogenesis. ICAM-1 expression-induced TNF-␣ regulated by LacCer and D-PDMP inhibited the expression of ICAM-1 expression in endothelial cells. The ␣ v ␤ 3 integrin is expressed in bone-resorbing osteoclasts (47) (48) (49) . Because the ␣ v ␤ 3 integrin binds ligands via the arginine-glycine-aspartic acid (RGD) sequence, osteoclastic bone resorption in vitro can be inhibited by the addition of the RGD peptide or antibody against ␣ v ␤ 3 integrins (47, 50 -52). Specific gangliosides have been shown to be associated with integrins at focal contacts (53. 54) and to modulate integrin-mediated adhesion (55, 56) . In neuronal cells, binding to disialogangliosides by tenascin or anti-GD2 antibody causes inhibition of protein kinase C and prevention of integrin-dependent adhesion to fibronectin, resulting in inhibition of neurite outgrowth (57, 58) . Therefore, GM1, which is not expressed in GM2/GD2-TϪ/Ϫ mice, increased after RANKL stimulation; this might be important to TRAP-positive mononuclear and multinuclear cell formation, especially for cell-to-cell attachment and fusion. However, the difference in differentiation into osteoclasts for GM2/ GD2ϩ/Ϫ versus Ϫ/Ϫ is only marginal. In knockout mice, other unexpected factors may support the formation of the osteoclast.
In D-PDMP treatment, ceramide was increased, and sphingosine and sphinganine expression was not affected by D-PDMP in purified bone marrow cells. In tumor cells, D-PDMP causes growth arrest and apoptosis because of an increase of ceramide rather than an decrease of GSLs (59, 60) . To determine which increased ceramide and decreased GSLs are important for the inhibiting effect of osteoclast differentiation, we added the C2-ceramide sphingosine and GSLs with M-CSF and RANKL to the culture medium. Adding C2-ceramide and sphingosine did not affect the osteoclast differentiation induced by M-CSF and RANKL without D-PDMP. The apoptosis of osteoclasts was not induced by C2-ceramide (data not shown). C2-ceramide strongly inhibited F-actin ring formation of and bone resorption by osteoclast (61) . In our culture system, ceramide did not affect TRAP-positive mononuclear and multinuclear cell formation. The ceramide concentration in cells may be important for actin ring formation and resorptional function in osteoclasts (61) but not TRAP-positive cell formation.
Exogenously generated LacCer recovered the TRAP-positive mononuclear cell formation in D-PDMP treated cells. GM3 and GM1 were also affected with these recovered effects, but no other glycolipids, GlcCer, GD3, or C2-ceramide (data not shown). GSLs, in particular the unique GSL LacCer, play a pivotal role in the biosynthesis of complex glycosphingolipids. LacCer, a precursor of gangliosides, is expressed ubiquitously all over the body. Exogenous LacCer stimulates the activation of ERK1 and the expression of c-fos transcription factor (62) . In endothelial cells, TNF-␣ induces the expression of LacCer synthesis. This inductive LacCer generates superoxide production and ICAM-1 expression (63). These results indicate that inhibition of osteoclast differentiation by D-PDMP is the cause of the decreased GSLs, especially LacCer, rather than increased ceramide.
In D-PDMP-treated bone marrow cells, RANKL-induced IB phosphorylation and ERK1/2 activation were reduced. IB phosphorylation induced the activation of the NF-B signaling pathway. This signaling is important for osteoclast differentiation (3). In fact, osteopetrosis caused by deficient osteoclast formation occurs in NF-B knockout mice (64) . The inhibitory effect of osteoclastogenesis with D-PDMP on bone marrow cells results in down-regulation of the NF-B signaling pathway. M-CSF also induced the expression of its receptor RANK. This induction of RANK was down-regulated by D-PDMP. These results indicate that prevention of osteoclast formation induced by D-PDMP is caused by down-regulation of RANKL signaling, IB, and ERK1/2 phosphorylation. In addition, M-CSF-induced phosphorylation of ERK1/2 is also inhibited by D-PDMP. D-PDMP also inhibited the expression of RANK induced by M-CSF. In the absence of M-CSF, cells did not respond to RANKL, for example phosphorylation of IB and MAPK was not observed after RANKL only (data not shown). These results indicate that the inhibitory effects of osteoclast formation by D-PDMP in our system consist of two possibilities. One is that the reduced expression of RANKL was induced by inhibition of M-CSF signaling. Second, the reduced signaling of RANKL was caused by the phosphorylation of IB and ERK1/2. In either case, total RANKL signaling was reduced, and TRAP-positive cell formation of purified bone marrow cell was completely inhibited by D-PDMP.
The addition of LacCer to the culture medium returned the phosphorylation levels back to the D-PDMP-untreated levels. LacCer recovered RANKL-induced ERK1/2 and IB phosphorylation, but we did not observe TRAP-positive multinuclear cell formation in LacCer-treated cells. Other glycolipids, for example GM3 and GM1, which increased after stimulation of M-CSF and RANKL, may be necessary to form the TRAPpositive multinuclear cells. However, treatment with GM3 or GM1 alone did not induce TRAP-positive multinuclear cell formation.
Why LacCer specifically induced the expression and activation of RANK in D-PDMP-treated osteoclast precursor cells is not clearly understood from our study. Previously, our studies with PC12 cells revealed that changing the cell surface glycolipids affected high affinity nerve growth factor receptor TrkA activation and phosphorylation of both ERK1 and ERK2. In PC12 cells, gangliosides regulated the TrkA dimer formation and phosphorylation (65) . Exogenous generated LacCer might modify the conformation of the RANK molecule. Two questions, whether LacCer binds to RANK and what the mechanisms are underlying the conformational change of RANK in osteoclasts, are now under investigation in our laboratory.
The results obtained in this study strongly suggest the important roles of glycosphingolipids, specifically LacCer, in the regulation of the initiation step of osteoclast differentiation and especially TRAP-positive mononuclear cell formation. These findings may be useful for the development of therapeutic agents to treat bone-resorbing diseases.
